metoclopramide has been researched along with Carcinoma, Non-Small Cell Lung in 11 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 9.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 9.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 7.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight." | 6.67 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ( Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991) |
| "19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters." | 6.66 | [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ( Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988) |
| "Intravenous antiemetic combinations containing a 5-HT3 receptor antagonist (like metoclopramide, ondansetron, or granisetron) with dexamethasone have become the standard therapy for the treatment of acute chemotherapy-induced vomiting." | 5.08 | Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin. ( Clark, RA; Cleri, LB; Gralla, RJ; Kris, MG; Pisters, KM; Tyson, LB, 1995) |
| "The clinical efficacy and tolerability of a new nasal spray formulation of metoclopramide (MTC) was evaluated in terms of its ability to prevent the nausea and vomiting induced by a moderately emetic chemotherapy (cisplatin 20 mg/m2 weekly as radioenhancer+radiotherapy for a fractionated total of 60 Gy) in 12 patients with non-small-cell lung cancer, stage IIIB." | 5.07 | Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study. ( Confalonieri, M; Dimaiuta, M; Scanni, A; Tomirotti, M, 1994) |
| "The usefulness of alprazolam (minor tranquilizer) used in combination with metoclopramide plus methylprednisolone for the prevention and control of emesis induced by chemotherapies, including 5-day continuous intravenous infusion of cisplatin (25 mg/m2/day) for advanced lung cancer, was evaluated using a double-blind randomized crossover design." | 5.07 | Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis. ( Mori, K; Saito, Y; Tominaga, K, 1993) |
| "In order to decide the administration method of metoclopramide for prevention or control of chemotherapy-induced nausea and vomiting in multidrug chemotherapy, with cisplatin 5-day continuous intravenous infusion (25 mg/m2/day) for patients with advanced lung cancer, a randomised crossover study of intermittent bolus infusion (1 mg/kg, 30 min, every 8 h, day 1-5) and continuous infusion (3 mg/kg/24 h, 120 h) of metoclopramide was performed." | 5.07 | Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin. ( Miyazawa, N; Mori, K; Saitou, Y; Tominaga, K, 1991) |
| "To evaluate the efficacy of a combined therapy of prednisolone and alprazolam for controlling cisplatin-induced delayed emesis, a study involving 14 non-small cell lung cancer patients receiving cisplatin (80 mg/m2) was conducted." | 3.68 | [A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis]. ( Horio, Y; Iwahara, T; Minami, H; Sakai, S; Shibagaki, T; Shimokata, K; Watanabe, A, 1990) |
| "Metoclopramide was administered by continuous infusion to two groups each of 14 patients on chemotherapy, randomized to receive either doses adjusted to individual pharmacokinetic parameters or doses adjusted as usual to body weight." | 2.67 | Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis. ( Brechot, JM; Chastang, C; Delattre, C; Dupeyron, JP; Laaban, JP; Rochemaure, J, 1991) |
| "19 mg/l with doses which varied considerably owing to marked scattering of pharmacokinetic parameters." | 2.66 | [Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach]. ( Brechot, JM; Delattre, C; Delfour, C; Dupeyron, JP; Guyon, F; Lebeau, B; Rochemaure, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 9 (81.82) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomirotti, M | 1 |
| Dimaiuta, M | 1 |
| Confalonieri, M | 1 |
| Scanni, A | 1 |
| Yoshimura, A | 1 |
| Yamano, Y | 1 |
| Gemma, A | 1 |
| Yoshimori, K | 1 |
| Hayashihara, K | 1 |
| Taniguchi, Y | 1 |
| Uematsu, K | 1 |
| Shibuya, M | 1 |
| Kudoh, S | 1 |
| Niitani, H | 1 |
| Cullen, MH | 1 |
| Mori, K | 2 |
| Saito, Y | 1 |
| Tominaga, K | 2 |
| Cleri, LB | 1 |
| Kris, MG | 1 |
| Tyson, LB | 1 |
| Pisters, KM | 1 |
| Clark, RA | 1 |
| Gralla, RJ | 1 |
| Inoue, S | 1 |
| Endo, K | 2 |
| Ichimura, H | 1 |
| Brechot, JM | 2 |
| Dupeyron, JP | 2 |
| Delattre, C | 2 |
| Chastang, C | 1 |
| Laaban, JP | 1 |
| Rochemaure, J | 2 |
| Saitou, Y | 1 |
| Miyazawa, N | 1 |
| Watanabe, A | 1 |
| Horio, Y | 1 |
| Minami, H | 1 |
| Shibagaki, T | 1 |
| Iwahara, T | 1 |
| Sakai, S | 1 |
| Shimokata, K | 1 |
| Navari, RM | 1 |
| Guyon, F | 1 |
| Delfour, C | 1 |
| Lebeau, B | 1 |
10 trials available for metoclopramide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Efficacy and tolerability of nasally administered compared to parenterally administered metoclopramide in the symptomatic treatment of chemotherapy-induced emesis in cancer outpatients. A controlled clinical study.
Topics: Administration, Intranasal; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; | 1994 |
[An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 1993 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone. Double-blind randomized crossover study in patients with cisplatin-induced emesis.
Topics: Adult; Aged; Alprazolam; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non | 1993 |
Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1995 |
[Anti-emetic treatment for patients with non-small cell lung cancer after chemotherapy, usefulness of preventive combination of anti-emetic agents and importance of psychiatric aspect of patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell | 1999 |
Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Resp | 1991 |
Comparison of continuous and intermittent bolus infusions of metoclopramide during 5-day continuous intravenous infusion with cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1991 |
Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Dexamethasone; Diphenhydramine; Dr | 1989 |
[Dosage adjustment of metoclopramide for controlling vomiting induced by cisplatin: pharmacokinetic approach].
Topics: Adult; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Lung Neoplasm | 1988 |
1 other study available for metoclopramide and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
[A combined anti-emesis therapy of oral prednisolone and alprazolam for cisplatin-induced delayed emesis].
Topics: Administration, Oral; Adult; Aged; Alprazolam; Antineoplastic Combined Chemotherapy Protocols; Carci | 1990 |